Put Options

9 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $186,660 - $234,600
8,500 New
8,500 $220,000
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $40,340 - $47,860
-2,000 Reduced 15.75%
10,700 $253,000
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $513,975 - $644,271
-26,700 Reduced 67.77%
12,700 $304,000
Q3 2023

Nov 14, 2023

BUY
$19.04 - $22.74 $750,176 - $895,955
39,400 New
39,400 $860,000
Q1 2020

May 15, 2020

SELL
$14.46 - $21.8 $80,976 - $122,080
-5,600 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$15.15 - $18.89 $84,840 - $105,784
5,600 New
5,600 $99,000
Q3 2019

Nov 14, 2019

SELL
$17.68 - $22.65 $436,696 - $559,455
-24,700 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $56,790 - $74,250
-3,000 Reduced 10.83%
24,700 $528,000
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $542,920 - $685,852
27,700 New
27,700 $659,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.